

1fw

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/705,282	
	Filing Date	11/10/2003	
	First Named Inventor	Chackalamannil	
	Art Unit	1625	
	Examiner Name	To Be Assigned	
Total Number of Pages in This Submission	6	Attorney Docket Number	CV01185K1X

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO 1449 (2); References (29); Post Card
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gerard E. Reinhardt / Reg. No. 43,041
Signature	<i>Gerard E. Reinhardt</i>
Date	July 28, 2004

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.	
Typed or printed name	Gerard E. Reinhardt
Signature	<i>Gerard E. Reinhardt</i>
Date	July 28, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT CV01185K1X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----X
In re Application of:

S. Chackalamannil et al

Serial No.: 10/705,282

Filing date: 11/10/2003

For: "Methods of Use of Thrombin
Receptor Antagonists"
-----X

: Examiner: To Be Assigned

: Group Art Unit: 1625

: Attorney Docket No.: CV01185K1X

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the following documents cited in the specification of the subject application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Patent:

WO 01 00576 A1
WO 01 00656 A2
WO 01 00657 A2
WO 01 00659 A1
WO 02 071847 A1
WO 02 076965 A1
WO 02 085850 A1
WO 02 088092 A1

Publications:

Ahn, Ho-Sam, Nonpeptide thrombin receptor antagonists, *Drugs of the Future*, 26(11), (2001)pp. 1065-1085.

Chan, Barden et al., Antiangiogenic property of human thrombin, *Microvascular Research*, (2003), 66(1), pp. 1-14.

Chang, M.C. et al., Thrombin-stimulated growth, clustering, and collagen lattice contraction of human gingival fibroblasts is associated with its protease activity, *Journal of Periodontology*, (2001), 72(3), pp. 303-13.

Chambers, R.C. et al., Coagulation cascade proteases and tissue fibrosis, *Biochemical Society Transactions*, 30(2), (2002), pp. 194-200.

Cunningham, Malcolm A. et al., Protease-activated Receptor 1 Mediates Thrombin-dependent, Cell-mediated Renal Inflammation in Crescentic Glomerulonephritis, *J. Exp. Med*, Vol. 191, No. 3, Feb. 7, 2000, pp 455-461.

D'Andrea, Michael R. et al, Expression of protease-activated receptor-1,-2,-3 and —4 in control and experimentally inflamed mouse bladder, *American Journal of Pathology*, 2003, 162(3), pp. 907-923.

Even-Ram, Sharona et al., Thrombin receptor overexpression in malignant and physiological invasion processes, *Nature Medicine*, Vol. 4, No. 8, (1998) pp.909-914.

Heckert, Olaf, et al., Sex Steroids Used in Hormonal Treatment Increase Vascular Procoagulant Activity by Inducing Thrombin Receptor (PAR-1) Expression, *Circulation*, (2001), 104, pp.2826 – 2831.

Jurk, Kerstin et al., Loss of Intact Seven-Transmembrane-Thrombin Receptor on the Platelet Surface of Patients with Acute Ischemic Stroke, *Circulation*, Vol. 98, 17S Abstract #2382, (1998) pp. I-453.

Kaufmann, R. et al., Meizothrombin, an intermediate of prothrombin cleavage potentially activates renal carcinoma cells by interaction with PAR-type thrombin receptors, *Oncology Reports*; 10 (2), (2003) pp. 493-496.

Meli, Rosaria et al., Thrombin and PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells, *Journal of Neurochemistry*, 79(3), (2001), pp. 556-563.

Nguyen, Quang-De et al., RhoA- and RhoD-dependent regulatory switch of G α subunit signaling by PAR-1 receptors in cellular invasion, *FASEB Journal*, 2002, 16(6), pp. 565-576.

Remenar, Julius F., et al. Crystal Engineering of Novel Cocrystals of a Triazole Drug with 1,4-Dicarboxylic Acids, *J. A. Chem. Soc.*, Vol. 125 No. 8, (2003), pp. 8456-8457.

Roche, Nicolas et al., Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 alveolar macrophages, *Journal of Allergy and Clinical Immunology*, 111(2), (2003), pp. 367-373.

Schiller, H. et al., Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro, *Int'l. J. of Clinical Pharmacology and Therapeutics*, 40(8), (2002), pp. 329-335.

Strukova, S.M. et al., Thrombin, a regulator of reparation processes in wound healing, *Bioorganicheskaya Khimiya*, 24(4), (1998), pp. 288-292.

Tanaka, Nobuhisa et al., Thrombin-induced Ca^{2+} mobilization in human gingival fibroblasts is mediated by protease-activated receptor-1(PAR-1), *Life Sciences* 73 (2003), pp. 301-310.

Tellez, Carmen et al., Role and regulation of the thrombin receptor (PAR-1) in human melanoma, *Oncogene* 22, (2003) pp. 3130-3137.

Tognetto, Michele et al., Proteinase-activated receptor-1(PAR-1) activation contracts the isolated human renal artery in vitro, *British Journal of Pharmacology*, 139 (1), (2003) pp. 21-27.


Vogel, S.M. et al., Abrogation of thrombin-induced increase in pulmonary microvascular permeability in PAR-1 knockout mice, *Physiol Genomics*, 4(2), (2000) pp. 137-145.

Wang, Junru et al., Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: possible link between endothelial dysfunction and chronic radiation fibrosis, *American Journal of Pathology*, 160(6), (2002) pp. 2063-72.


The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365. If the Examiner has any questions, the Examiner is invited to contact the undersigned

Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1,1990
Kenilworth, NJ 07033
Tel: (908) 298-2960
Fax: (908) 298-5388

Respectfully submitted,



Gerard E. Reinhardt
Attorney for Applicants
Reg. No. 43,041
July 28, 2004



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:
CV01185K1X

APPLICATION NO.:
10/705,282

APPLICANT:
S. Chackalamannil et al

FILING DATE:
11/10/2003

GROUP:
1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AA WO 01 00576 A1	01/04/01	WIPO				
	AB WO 01 00656 A2	01/04/01	WIPO				
	AC WO 01 00657 A2	01/04/01	WIPO				
	AD WO 01 00659 A1	01/04/01	WIPO				
	AE WO 02 071847 A1	09/19/02	WIPO				
	AF WO 02 076965 A1	10/03/02	WIPO				
	AG WO 02 085850 A1	10/31/02	WIPO				X
	AH WO 02 088092 A1	11/07/02	WIPO				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Ahn, Ho-Sam et al., Nonpeptide thrombin receptor antagonists, <i>Drugs of the Future</i> , 26 (11), (2001): pp. 1065 – 1085.
AJ	Chan, Barden et al., Antiangiogenic property of human thrombin, <i>Microvascular Research</i> , 66(1) (2003), pp. 1 – 14.
AK	Chang, M.C.et al., Thrombin-stimulated growth, clustering, and collagen lattice contraction of human gingival fibroblasts is associated with its protease activity, <i>Journal of Periodontology</i> , 72(3), (2001), pp. 303-13.
AL	Chambers, R.C.et al., Coagulation cascade proteases and tissue fibrosis, <i>Biochemical Society Transactions</i> , 30(2), (2002), pp. 194-200.
AM	Cunningham, Malcolm A. et al., Protease-activated Receptor 1 Mediates Thrombin-dependent, Cell-mediated Renal Inflammation in Crescentic Glomerulonephritis, <i>J. Exp. Med</i> , Vol. 191(3), (2000), pp 455-461.
AN	D'Andrea, Michael R. et al., Expression of Protease-Activated Receptor-1,-2,-3 and -4 in Control and Experimentally Inflamed Mouse Bladder, <i>American Journal of Pathology</i> , 162(3), (2003), pp. 907-923.
AO	Even-Ram, Sharona, et al., Thrombin receptor overexpression in malignant and physiological invasion processes, <i>Nature Medicine</i> , Vol. 4 (8), (1998), pp.909-914.
AP	Heckert, Olaf, et al., Sex Steroids Used in Hormonal Treatment Increase Vascular Procoagulant Activity by Inducing Thrombin Receptor (PAR-1) Expression, <i>Circulation</i> , (2001), Vol. 104, pp.2826-2831.
AQ	Jurk, Kerstin et al., Loss of Intact Seven-Transmembrane-Thrombin Receptor on the Platelet Surface of Patients with Acute Ischemic Stroke, <i>Circulation</i> , Vol. 98, 17S Abstract #2382, (1998), pp. I-453.
AR	Kaufmann, R. et al., Meizothrombin, an intermediate of prothrombin cleavage potentially activates renal carcinoma cells by interaction with PAR-type thrombin receptors, <i>Oncology Reports</i> ; 10(2), (2003), pp. 493-496.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

40681

AS	Meli, Rosaria et al., Thrombin and PAR-1 activating peptide increase iNOS expression in cytokine-stimulated C6 glioma cells, <i>Journal of Neurochemistry</i> , 79(3), (2001) pp. 556-563.
AT	Nguyen, Quang-De et al., RhoA- and RhoD-dependent regulatory switch of G α subunit signaling by PAR-1 receptors in cellular invasion, <i>FASEB Journal</i> , 16(6), (2002) pp. 565-576
AU	Remenar, Julius F., et al. Crystal Engineering of Novel Cocrystals of a Triazole Drug with 1,4-Dicarboxylic Acids, <i>J.A. Chem Soc.</i> , Vol. 125 No. 28, (2003), pp.8456-8457.
AV	Roche, Nicolas et al., Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 alveolar macrophages, <i>Journal of Allergy and Clinical Immunology</i> , 111 (2), (2003), pp. 367-373.
AW	Schiller, H. et al., Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro, <i>Int'l. J. of Clinical Pharmacology and Therapeutics</i> , 40 (8), (2002), pp. 329 – 335.
AX	Strukova, S.M. et al, Thrombin, a regulator of reparation processes in wound healing, <i>Bioorganicheskaya Khimiya</i> , 24 (4), (1998), pp. 288-292.
AY	Tanaka, Nobuhisa et al, Thrombin-induced Ca ²⁺ mobilization in human gingival fibroblasts is mediated by protease-activated receptor-1(PAR-1), <i>Life Sciences</i> 73 (2003), pp. 301-310
AZ	Tellez, Carmen et al., Role and regulation of the thrombin receptor (PAR-1) in human melanoma, <i>Oncogene</i> 22, (2003), pp. 3130-3137.
BA	Tognetto, Michele et al., Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro, <i>British Journal of Pharmacology</i> , 139(1), (2003) pp. 21-27.
BB	Vogel, S.M. et al, Abrogation of thrombin-induced increase in pulmonary microvascular permeability in PAR-1 knockout mice, <i>Physiol Genomics</i> , 4(2), (2000), pp. 137-145.
BC	Wang, Junru et al, Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: possible link between endothelial dysfunction and chronic radiation fibrosis, <i>American Journal of Pathology</i> , 160(6), (2002) pp. 2063-72.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.